Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation

US10961583B2 · kind B2 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Yurong Xin · Tarrytown, US
• Jesper Gromada · Scarsdale, US
• Xiping Cheng · Millwood, US
• Frederick Dewey · Winchester, US
• Tanya Teslovich Dostal · Tarrytown, US
• Claudia Schurmann · Tarrytown, US
• Aris Baras · Tarrytown, US
• Noura S. Abul-Husn · New York, US

Key dates

• Filing date: Oct 11, 2018
• Grant date: Mar 30, 2021
• Expiry date: Oct 11, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver disease by inhibiting HSD17B13. The disclosure also provides methods of treating a subject who is PNPLA3 Ile148Met+ by administering an inhibitor of HSD17B13. The disclosure also provides method of detecting a PNPLA3 Ile148Met variant and functional HSD17B13 in a subject. The disclosure also provides method of identifying a subject having a protective effect against liver disease. The disclosure also provides inhibitors of HSD17B13 for use in the treatment of a liver disease.